Willow Biosciences Inc
Atlas Energy Corp., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. The company was formerly known as Willow Biosciences … Read more
Willow Biosciences Inc (CANSF) - Total Assets
Latest total assets as of September 2025: $28.12 Million USD
Based on the latest financial reports, Willow Biosciences Inc (CANSF) holds total assets worth $28.12 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Willow Biosciences Inc - Total Assets Trend (2008–2024)
This chart illustrates how Willow Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Willow Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Willow Biosciences Inc's total assets of $28.12 Million consist of 26.4% current assets and 73.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.4% |
| Accounts Receivable | $39.00K | 1.6% |
| Inventory | $56.00K | 2.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Willow Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Willow Biosciences Inc's current assets represent 26.4% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 13.4% of total assets in 2024, up from 8.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 2.3% of total assets.
Willow Biosciences Inc Competitors by Total Assets
Key competitors of Willow Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Senton Energy Co. Ltd. A
SHE:001331
|
China | CN¥1.68 Billion |
|
Shaanxi Provincial Natural Gas Co Ltd
SHE:002267
|
China | CN¥13.96 Billion |
|
Zhuhai Winbase International Chemical Tank Terminal Co Ltd
SHE:002492
|
China | CN¥2.32 Billion |
|
HENGYANG PETROCHEM (5HY.SG)
STU:5HY
|
Germany | €535.36 Million |
|
Shanxi Guoxin Energy Co Ltd A
SHG:600617
|
China | CN¥25.35 Billion |
|
Nanjing Tanker Corp
SHG:601975
|
China | CN¥13.19 Billion |
|
China Merchants Energy Shipping Co Ltd
SHG:601872
|
China | CN¥77.88 Billion |
|
Anhui Province Natural Gas Development Co Ltd
SHG:603689
|
China | CN¥7.57 Billion |
Willow Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Willow Biosciences Inc generates 1.87x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Willow Biosciences Inc is currently not profitable relative to its asset base.
Willow Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 171.48 | 0.80 | 10.88 |
| Quick Ratio | 171.48 | 0.76 | 10.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $27.96 Million | $ -392.00K | $ 15.47 Million |
Willow Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Willow Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.55 |
| Latest Market Cap to Assets Ratio | 1.15 |
| Asset Growth Rate (YoY) | -62.7% |
| Total Assets | $2.49 Million |
| Market Capitalization | $2.85 Million USD |
Valuation Analysis
Above Book Valuation: The market values Willow Biosciences Inc's assets above their book value (1.15 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Willow Biosciences Inc's assets decreased by 62.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Willow Biosciences Inc (2008–2024)
The table below shows the annual total assets of Willow Biosciences Inc from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.49 Million | -62.70% |
| 2023-12-31 | $6.67 Million | -63.23% |
| 2022-12-31 | $18.15 Million | -48.17% |
| 2021-12-31 | $35.02 Million | +60.15% |
| 2020-12-31 | $21.86 Million | -35.47% |
| 2019-12-31 | $33.88 Million | +3403.87% |
| 2018-12-31 | $967.03K | +33.53% |
| 2017-12-31 | $724.18K | -57.39% |
| 2016-12-31 | $1.70 Million | -29.64% |
| 2016-06-30 | $2.42 Million | +87.21% |
| 2015-12-31 | $1.29 Million | -33.64% |
| 2014-12-31 | $1.94 Million | -13.04% |
| 2013-12-31 | $2.24 Million | +9.83% |
| 2012-12-31 | $2.04 Million | -31.95% |
| 2011-12-31 | $2.99 Million | -22.65% |
| 2010-12-31 | $3.87 Million | -26.00% |
| 2009-12-31 | $5.23 Million | +38.94% |
| 2008-12-31 | $3.76 Million | -- |